By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.


May 1991


CEO and Founder: Mark Capone

CMO (Medical): Richard Wenstrup

CFO: Bryan Riggsbee

CSO (Scientific): Jerry Lanchbury


Please click here for Myriad Genetics job opportunities.


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Myriad Genetics
Symbol: MYGN

Company News
Myriad Genetics (MYGN) Release: Genesight Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics 2/23/2017 8:25:06 AM
Myriad Genetics (MYGN)’s Bracanalysis CDx Test Successfully Identified Metastatic Breast Cancer Patients With Improved Outcomes From AstraZeneca PLC (AZN)'s PARP Inhibitor, Olaparib 2/17/2017 8:28:47 AM
Myriad Genetics (MYGN)’s Prolaris Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer 2/17/2017 8:27:20 AM
Myriad Genetics (MYGN) Reports Fiscal Second-Quarter 2017 Financial Results 2/8/2017 7:45:55 AM
Myriad Genetics (MYGN) Release: The Endopredict Test Receives Positive Coverage Decisions From Multiple Blue Cross Blue Shield Affiliate Plans 1/6/2017 7:55:24 AM
Myriad Genetics (MYGN) Release: EndoPredict Reviewed By Blue Cross Blue Shield Association’s Evidence Street 1/5/2017 7:40:50 AM
Myriad Genetics (MYGN) Release: The EndoPredict Test Significantly Outperforms The First-Generation Test In Predicting The Risk Of Node-Negative And Node-Positive Breast Cancer Recurrence 12/9/2016 6:23:25 AM
How Myriad Genetics (MYGN) Strategized to Undermind Its New Genetic Testing Competitors 11/29/2016 7:10:28 AM
Myriad Genetics (MYGN) Will Present Results From Six Breast Cancer Studies At SABCS 11/28/2016 11:26:47 AM
Myriad Genetics (MYGN) Will Seek Japanese Regulatory Approval For BRACAnalysis CDx 11/7/2016 10:05:23 AM